Diabetes

Amy C. Nieto explains essential guidelines for managing diabetes during Ramadan, ensuring safe fasting practices and optimal health for patients.

A new study reveals that individuals with type 2 diabetes (T2D) face significant financial hardships, impacting their health and medication adherence.

GLP-1 receptor agonists show promise in improving survival rates for older patients with cancer who have type 2 diabetes (T2D), highlighting their potential in oncology.

Insights from the American Diabetes Association 85th Scientific Sessions.

Pharmacists are pivotal in optimizing GLP-1 receptor agonist therapy.

Critically ill patients treated with a pharmacist-managed insulin protocol achieved higher rates of glucose control than those treated with conventional methods.

Different dietary strategies, including intermittent energy restriction, enhance weight loss and blood sugar control in those with type 2 diabetes (T2D) and obesity.

Once-weekly efsitora alfa shows promising hemoglobin A1C reduction in type 2 diabetes (T2D), simplifying insulin therapy and reducing injection frequency significantly.

Obesity and type 2 diabetes in youth significantly increase the risk of osteoporosis and fractures, highlighting the need for early intervention and healthy habits.

Finerenone emerges as a promising treatment for patients with diabetes and chronic kidney disease, significantly reducing cardiovascular and renal risks.

A maternal inflammatory diet during pregnancy raises the risk of offspring developing type 1 diabetes, highlighting the impact of nutrition on early health.

GLP-1 medications like semaglutide face scrutiny over compounded versions, raising concerns about patient safety and counterfeit products in diabetes treatment.

Simplifying complex information through illustrations has consistently helped patients feel that managing type 1 diabetes is achievable.

As compounded medications gain popularity amid drug shortages, concerns about safety, quality, and regulation have intensified, making Pharmacy Compounding Accreditation Board (PCAB) accreditation a safeguard for consistency, oversight, and public trust in compounding pharmacy practices.

A groundbreaking trial shows zimislecel significantly reduces insulin dependence in patients with type 1 diabetes, offering hope for a functional cure.

SGLT2 inhibitors improve diabetes management but may cause erythrocytosis without increasing blood clot risks, highlighting the need for careful monitoring.

New research reveals that combining bimagrumab and semaglutide enhances fat loss while preserving muscle mass, revolutionizing obesity treatment strategies.

The session highlighted tirzepatide’s unique mechanism of action, based on comprehensive clinical data and real-world evidence.

Oral semaglutide shows promising cardiovascular benefits for type 2 diabetes patients, reducing major adverse events by 14% in the SOUL trial.

CagriSema shows promising weight loss and metabolic benefits in recent trials, offering new hope for obesity and type 2 diabetes management.

Semaglutide shows promise in enhancing walking ability and reducing disease progression in patients with type 2 diabetes and peripheral artery disease.

Expert shares key upcoming sessions at the American Diabetes Association 85th Scientific Sessions.

New research reveals a significant link between type 2 diabetes, obesity, and fatty liver disease.

New research reveals how individual blood glucose responses to carbohydrates vary, highlighting the importance of personalized dietary approaches for diabetes management.

Patients with diabetes using glucagon-like peptide-1 (GLP-1) drugs face double the risk of developing neovascular age-related macular degeneration, highlighting crucial ocular health concerns.

CKD is a complication of diabetes. Emerging treatments aim to optimize management and reduce risks. Pharmacists are key in applying new evidence to clinical practice.

Ranibizumab injection (Susvimo; Genentech) could offer long-lasting vision preservation and reduce the need for frequent injections in patients with diabetic retinopathy.

Research reveals pioglitazone, a diabetes drug, may slow prostate cancer progression, offering new hope for patients with both conditions.

Diabetic ketoacidosis poses serious risks for patients with diabetes, requiring urgent treatment to prevent life-threatening complications and ensure recovery.